Objective: The purpose of this study was to determine whether BN52021, a platelet-activation 
Introduction
Brain injury is a common disease that threatens human health [1] . Brain injury can be divided into types including primary and secondary [2] . Secondary brain injury or acute neuroinflammation occurs within hours or days after a brain injury, and this brain injury consists of neuron damage and nervous system dysfunction that is associated with specific biochemical processes. Learning and memory deficits represent common sequelae of secondary injury to the brain, and could seriously affect the quality of life of patients [3] . Various neuroinflammatory factors play an important role in secondary brain damage, including interleukin1-α, interleukin1-β, prostaglandins, tumor necrosis factor, etc. PAF represents one of the strongest inflammatory factors in the central nervous system. Previous studies have found that a marked rise in PAF and prostaglandin levels were associated with brain inflammation [4] . Therefore, PAF is the key link in the regulation of neuroinflammation. The purpose of the current study was to investigate whether BN52021, PAFR antagonist, could provide neuroprotection from the cytotoxic effects induced by PAF in vitro and in vivo.
Materials and Methods

Cell Culture
PC12 cells were cultured in MEM/F-12 (1:1) medium (Invitrogen, USA) supplemented with 10% fetal calf serum (FCS, Invitrogen), 100 U/ml penicillin, and 100 μg/ml streptomycin. The PC12 cells were cultured in a humidifed atmosphere containing 5% CO 2 at 37˚C. When the cells reached the proper confluence, they were placed into a serum-free medium. The cells were incubated with PAF (0.1, 0.3, 0.6 μmol/L) for 24 hours or incubated with PAF (0.3 μmol/L) for three hours. Without changing the culture medium, the cells were then treated with BN52021 (Long He Co.; low dose group: 1 mg/L; high dose group: 5 mg/L) for an additional 48 hours.
MTT Assay of Cell Viability
PC12 cells were plated at 5 × 10 4 cells/well (200 μl) into 96 well plates, and allowed to adhere and grow until they reached the required confluence. After drug treatment, the survival of cells was determined by MTT assay. Briefy, after incubation with 20 μl MTT (5 mg/ml, Sigma) at 37˚C for 3 hours, living cells containing MTT formazon crystals were made soluble in 200 μl dimethylsulfoxide (DMSO, Sigma). The absorbance of each well was measured using a microculture plate reader with a test wave length of 570 nm and a reference wave length of 655 nm. The light absorption value was measured to determine formazan absorption.
Measurement of Apoptosis by Flow Cytometry
To determine whether PAF-triggered cell death was apoptotic, we measured cell apoptosis using an AnnexinV-FITC Apoptosis Detection Kit (BD Pharmingen, USA) according to the manufacturer's instructions. Briefy, the cells were plated at a density of 5 × 10 5 cells/ml into six well plates, and cultured until the cells reached 70% confluence. After drug treatment, cells were trypsinized, collected by centrifugation. The cells were then resuspended in 200 μl of binding buffer (provided by the manufacturer). This buffer contained 5 μl of annexin V-FITC and propidium iodide (PI). The cells were incubated for 15 minutes at room temperature. All samples were kept on ice and analyzed immediately with a FACSCalibur flow cytometer (BD, USA).
Animal Preparation
Forty Sprague-Dawley rats (approximately 4 months old and weighing 200 g) were divided into four groups, including a control group, a model group, a low dose group and a high dose group. The rats were anesthetized with 20% urethane (1300 mg/kg, i.p). The rats first were placed in a stereotaxic instrument with the incisor bar set 3 mm below the earbars (i.e., plat skull), and the scalp was incised and retracted. A hole was drilled in appropriate location in the skull with a dental drill. PAF (0.3 μg/kg, dissolved in artificial CSF, 5 μg/μl) was injected into the fourth ventricle. Eight control rats were injected with artificial CSF. The next day after operation, the low dose and high dose group rats were treated with BN52021. BN52021 was first dissolved in DMSO, and then PBS was added at the following concentrations (i.p.): 0.01 mol/L PBS, 1 mg/kg PBS (low dose), and 5 mg/kg PBS (high dose).
Behavioral Testing
Behavioral testing began 6 days after injection (i.p.). The Morris water maze test was used to measure the rats' ability to learn and remember spatial cues. The navigational test was conducted in a dark airtight room. The pool was divided into four quadrants, and a platform was placed in one of the quadrants. The rats were randomly placed in the water from four different directions. The rats were then allowed 90 seconds to find the platform. If the rats failed to find the platform within 90 seconds, they were placed on the platform where they stayed for 30 seconds. This test was conducted once per day for 4 days. The platform was then removed, and the rats were placed in the center of the pool to find the platform in order to test their special memory. A computer recorded (1) the number of times that the rat passed the platform and (2) the percentage of swimming distance in the platform quadrant to the total distance.
Results
The Cytotoxicity of PAF
MTT assay of cell viability showed that the absorbance value decreased gradually with the increase of PAF concentration. The absorbance value of 4 PAF concentration groups was shown in Figure 1 . Measurement of Apoptosis by Flow Cytometry was shown in Figure 2 : As the concentration of PAF increased, the percentage of apopotosis of cells increased.
The Protection of BN52021 from PAF Cytotoxiciy
MTT Assay of Cell Viability to test PAF cytotoxicity was shown in 
Morris Water Test of Spatial Memory
The rats appeared normal and did not lose weight following the PAF injection. The training results of the four tests in place navigation test (i.e., evasive latency) are shown in Figure 5 . The percentage of swimming distance in the platform quadrant relative to the total dis- tance and the number of times the rats passed the platform are shown in Figure 6 . The control group and the two treatment groups showed significant increases in both the number of times passing the platform and the percentage of the swimming distance, as compared to the model group.
Discussions
The primary mechanism associated with secondary brain injury is neuroinflammation and cerebral edema. Therefore, the inhibition of neuroinflammation likely represents a crucial therapy for the treatment of secondary brain injury [5, 6] . As one of the str ngest inflammatory factors, PAF plays a key role in the modulation of neuroinflammation [7] . PAF is expressed in neurons as well as neuroglial cells, and previous studies report that PAF is increased after brain injury [8] . Therefore, a high dose of PAF could affect neurotoxicity [9] . Likewise, the PAFR antagonist-E5880 could protect neurons and neuroglial cells from neurotoxicity induced by glutamine [10] . In present study, PAF induced apoptosis and cell death when added to cultured PC12 cells. As the concentration of PAF increased, cell death increased in a similar manner. However, cell death markedly decreased when BN52021, a PAF antagonist, was administered prior to PAF. These findings demonstrate that BN52021 can protect PAF-induced cytotoxicity in vitro. Additionally, the central inflammatory response produced by the infusion of PAF produced a significant deficit in spatial memory, as measured by the Morris water maze. Interestingly, this memory deficit was completely attenuated by the coadministration of BN52021. These results indicate that a PAFR antagonist protects neurons and neuroglial cells from neuroinflammation as well as spatial memory deficits. Therefore, PAFR antagonists may be a relevant compound for the treatment of brain injury, and BN52021 would be important to assess in clinical trials for brain injury.
